Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Prevention02:59

Cancer Prevention

6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.0K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk.

JAMA network open·2026
Same author

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

Future oncology (London, England)·2026
Same author

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants.

JCO precision oncology·2026
Same author

Reply to "Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies".

Journal of clinical psychopharmacology·2026
Same author

Mapping the contributions of adjuvant tamoxifen, 20 years later.

Journal of the National Cancer Institute·2026

相关实验视频

Updated: May 15, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.8K

基于多基因的乳腺癌风险预测与患者管理的关联

Katherine Johansen Taber1, Elisha Hughes1, Alexander Gutin1

  • 1Myriad Genetics, Inc, Salt Lake City, UT.

JCO precision oncology
|May 7, 2025
PubMed
概括
此摘要是机器生成的。

综合风险得分 (CRS) 提高了乳腺癌风险预测. 具有较高CRS或Tyrer-Cuzick (TC) 评分的患者接受了更频繁的查乳房扫描,乳房MRI和遗传咨询,这表明对CRS结果的临床考虑.

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

185
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.0K

相关实验视频

Last Updated: May 15, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.8K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

185
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.0K

科学领域:

  • 在瘤学瘤学.
  • 遗传学 是一个遗传学.
  • 医疗信息学 医疗信息学

背景情况:

  • 乳腺癌 (BC) 风险预测通过将临床和多基因因素结合成综合风险评分 (CRS) 来提高.
  • CRS结果对现实世界患者管理策略的影响在很大程度上仍未被描述.

研究的目的:

  • 评估综合风险评分 (CRS) 结果如何影响乳腺癌 (BC) 风险的临床管理.
  • 评估基于CRS和Tyrer-Cuzick (TC) 风险分层的增强BC查和遗传咨询的采用情况.

主要方法:

  • 与BC风险管理评估的TC和CRS结果连接非识别的医疗/药房索赔数据.
  • 根据CRS和TC预测的终身风险 (≥20%与<20%) 将患者分为分层分为子队伍.
  • 在40岁以下的患者中,查性乳房显微镜 (SM) 的比率,乳房MRI和遗传咨询 (GC) 360天前后CRS测试使用McNemar测试和后勤回归.

主要成果:

  • 具有≥20%风险的亚队 (CRS+TC+,CRS+TC-,CRS-TC+) 显示SM (<40岁) 和乳房MRI后CRS测试显著增加.
  • 在CRS+TC+和CRS+TC-亚队列中,基因咨询的比例增加.
  • 在CRS-TC-亚队列中,这些管理策略没有显著增加,而其他组显示获得增强护理的几率明显更高.

结论:

  • 通过CRS或TC确定终身BC风险≥20%的患者更有可能获得增强的治疗.
  • 研究结果表明,临床医生积极将CRS结果纳入乳腺癌风险管理决策中.
  • 该研究强调了综合风险评分在指导个性化癌症查和预防策略方面的临床实用性.